65,437 trials
Homozygous Familial Hypercholesterolemia
Primary: Part A: Maximum Observed Serum Concentration (Cmax) of Evinacumab — 238 Milligrams per Liter (mg/L)
Cutaneous T-Cell Lymphoma/Mycosis Fungoides
Primary: Electrocardiograms (ECG) — 0 Participants
Recurrent Diffuse Large B-Cell Lymphoma · Recurrent High Grade B-Cell Lymphoma · Recurrent Transformed B-Cell Non-Hodgkin Lymphoma
Primary: Maximum Tolerated Dose (MTD) or Recommended Phase II Dose (RP2D) of Mogamulizumab in Combination With Pembrolizumab (Phase I) — 0; 1; 2; 0 Participants
Localized Osteosarcoma · Metastatic Osteosarcoma
Primary: Event-free Survival (EFS) — 74; 77; 55; 53 Percentage EFS — p=0.214
HIV
Primary: Proportion of Participants With an Undetectable HIV Viral Load — 107; 113 Participants
Lyme Borreliosis
Primary: Percentage of Participants With Solicited Local and Solicited Systemic Adverse Events (AEs) Within 7 Days After Vaccination 1 — 63.0; 59.3; 12.5; 60.4 Percentage of…
Clostridium Difficile Infection
Primary: Area Under the Concentration-Time Curve of Bezlotoxumab From Time 0 to Infinity (AUC0-inf) — 56100; 43200 hr*ug/mL
Health Behavior
Primary: Individual Participation in COVID-19 Testing — 25; 21 Participants — p=.6298
Meningococcal Immunisation · Healthy Volunteers
Primary: Percentage of Participants With Antibody Titers >=1:8 Against Meningococcal Serogroups A, C, W, and Y Measured by hSBA Following Vaccination With MenACYW Conjugate…
Alzheimer Disease
Primary: Level of Understanding — 17.8; 16.8; 15.1; 15.7 score on a scale (MacCAT-CR Und Trial 2)
Multiple Myeloma
Primary: Progression Free Survival by Independent Response Adjudication Committee (IRAC) — 11.20; 7.10 Months — p=0.001
Non-Small Cell Lung Cancer
Primary: Objective Response Rate (ORR) Per Investigator by Blood TMB (bTMB) Within PD-L1 Subgroup (TMB Cut-point = 16 Mutations/MB) — 30; 50; 58.8; 30.3 Percent of Participants
Parkinson Disease
Primary: Number of Participants With Treatment-Emergent Adverse Events — 221 Participants
Soft Tissue Sarcoma
Primary: Number of Participants That Experienced Dose Limiting Toxicities (DLTs) Using CTCAE, Version 4.0 — 0 participants
Parkinson Disease · Cognitive Dysfunction
Primary: Part A: Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) — 45.5 percentage of participants